Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Athira Pharma Inc

Current price
2.13 USD +0.07 USD (+3.40%)
Last closed 2.06 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 93 517 152 USD
Yield for 12 month -18.08 %
21.11.2021 - 28.11.2021

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington. Address: 18706 North Creek Parkway, Bothell, WA, United States, 98011

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

7.42 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-969 000 USD

Last Year

-1 048 000 USD

Current Quarter

-245 000 USD

Last Quarter

-244 000 USD

Key Figures ATHA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -126 125 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -37.97 %
PEG Ratio
Return On Equity TTM -64.42 %
Wall Street Target Price 7.42 USD
Revenue TTM
Book Value 3.41 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings Share -3.09 USD
Diluted Eps TTM -3.09 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ATHA

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ATHA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ATHA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA 0.4153
Price Book MRQ 0.7183

Financials ATHA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ATHA

For 52 weeks

1.33 USD 4.3 USD
50 Day MA 3.1 USD
Shares Short Prior Month 979 265
200 Day MA 2.5 USD
Short Ratio 1.81
Shares Short 1 009 444
Short Percent 3.59 %

Dynamics of changes in the value of assets




399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds



207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics



2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics